Is 8156.HK overvalued or undervalued?

8156.HK currently has a P/E ratio of -6.52. Relative to the sector average of 11.60, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Sinopharm Tech Holdings Limited stock?

Sinopharm Tech Holdings Limited trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 8156.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 8156.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 8156.HK to protect their purchasing power. Because 8156.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 8156.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 8156.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 8156.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks8156.HK

Sinopharm Tech Holdings Limited

HK$0.16+HK$0.00+1.27%

HKSE / HKD

Market cap

HK$101M

P/E

-6.5

EPS (TTM)

HK$-0.00

Dividend yield

0.00%

Beta

1.59

1Y return

-23.44%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$5M2021

$5M2022

$5M2023

$8M2024

$6M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity-0.66Low
Current ratio0.38
Cash ratio0.10
Net margin-20.1%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

8156.HK-6.5
Technology sector median11.6
S&P 50022.0

Trades about 156% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.00
Price to book-1.01
EPS (TTM)HK$-0.00
Payout ratio0%
FCF yield-4.27%

Range & risk

HK$0.15HK$0.35

Trading in the lower third of its 52-week band

Beta1.59

Profile

What Sinopharm Tech Holdings Limited actually does

Sinopharm Tech Holdings Limited functions as an investment holding enterprise, with its primary focus on lottery operations across mainland China and Hong Kong. The company diversifies its activities into several key areas: it supplies both hardware and software systems for lottery services; develops and implements "Internet Plus" solutions for various industries including healthcare, government administration, property leasing, and public security; engages in the manufacturing and distribution of personal protective equipment; and offers additional services such as corporate management, supply chain optimization, data analytics, and online trading of goods. Founded in 1999 and headquartered in Sha Tin, Hong Kong, the company rebranded to Sinopharm Tech Holdings Limited in June 2019, having previously traded as China Vanguard You Champion Holdings Limited.

CEO

Shuk Yi Kwok

Employees

Headquarters

Hong Kong

Founded

2002-11-12

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 8156.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

8156.HK has a beta of 1.59, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

Sinopharm Tech Holdings Limited